A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Investigational new drugs

• Publication date

  2008-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-007-9103-2PMID 18196204
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Application of the Iliac Artery in the Ex Vivo Reconstruction of Renal Arteries in Renal Transplantation: Retraction.

  2019cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)

  2007cited by this paper
• A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors.

  2006cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.

  2004cited by this paper
• Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days

  2004cited by this paper
• A phase III study of doxorubicin (A) versus cisplatin (P)/ interferonα-2b (I)/ doxorubicin (A)/ fluorouracil (F) combination chemotherapy (PIAF) for inoperable hepatocellular carcinoma (HCC).

  2004cited by this paper
• Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

  2003cited by this paper
• Pharmacotherapy of hepatocellular carcinoma

  2003influential reference
• Are there indications for chemotherapy in hepatocellular carcinoma?

  2003cited by this paper
• Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

  2002cited by this paper
• Past and future of the mitotic spindle as an oncology target.

  2001cited by this paper
• Prospective Validation of the Cancer of the Liver Italian Program (CLIP) Score: A New Prognostic System for Patients With Cirrhosis and Hepatocellular Carcinoma

  2000cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• The way things move: looking under the hood of molecular motor proteins.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis.

  2000cited by this paper
• Liver Transplantation for Hepatocellular Carcinoma

  1999cited by this paper
• Rising Incidence of Hepatocellular Carcinoma in the United States

  1999cited by this paper
• Rising incidence of hepatocellular carcinoma in the United States.

  1999cited by this paper
• The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line.

  1998cited by this paper
• A prospective randomized trial

  1995cited by this paper
• Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice.

  1992cited by this paper
• Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

  1988cited by this paper

• Decoding the Role of Kinesin Superfamily Proteins in Glioma Progression

  2025cites this paper
• Enhancement Effects of α4/α6‐Targeted Inhibitors on Eg5‐Microtubule Interaction

  2025cites this paper
• Kinesin Spindle Protein (KIF11) in Mitosis and Cancer

  2025cites this paper
• Mitotic Functions and Characters of KIF11 in Cancers

  2024cites this paper
• Regulation of KIF23 by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma.

  2024cites this paper
• The role of kinesin superfamily proteins in hepatocellular carcinoma

  2024cites this paper
• The role of kinesin family members in hepatobiliary carcinomas: from bench to bedside

  2024cites this paper
• The two sides of chromosomal instability: drivers and brakes in cancer

  2024cites this paper
• LncRNA NEAT1 suppresses cellular senescence in hepatocellular carcinoma via KIF11‐dependent repression of CDKN2A

  2023cites this paper
• KIF23 regulation by miR-107 controls replicative tumor cell fitness in mouse and human hepatocellular carcinoma

  2023cites this paper
• Drug resistance dependent on allostery: A P-loop rigor Eg5 mutant exhibits resistance to allosteric inhibition by STLC

  2022influential citation
• Synthesis and screening of novel 4-N-heterocyclic-2-aryl-6,7,8-trimethoxyquinazolines as antiproliferative and tubulin polymerization inhibitors.

  2022cites this paper
• Kinesin spindle protein inhibitors in cancer: from high throughput screening to novel therapeutic strategies

  2022cites this paper
• Second-Generation Antimitotics in Cancer Clinical Trials

  2021cites this paper
• KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo.

  2021cites this paper
• Kinesin superfamily proteins: roles in osteosarcoma.

  2021cites this paper
• Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers

  2021cites this paper
• Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer

  2021cites this paper
• Kinesin family members KIF2C/4A/10/11/14/18B/20A/23 predict poor prognosis and promote cell proliferation in hepatocellular carcinoma.

  2020cites this paper
• Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy.

  2020cites this paper
• Eg5 Targeting Agents : From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.

  2020cites this paper
• Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.

  2019cites this paper
• Filanesib for the treatment of multiple myeloma

  2019cites this paper
• Increased KIF15 Expression Predicts a Poor Prognosis in Patients with Lung Adenocarcinoma

  2018cites this paper
• A New Way to Treat Brain Tumors: Targeting Proteins Coded by Microcephaly Genes?

  2018cites this paper
• Suppression of spindly delays mitotic exit and exacerbates cell death response of cancer cells treated with low doses of paclitaxel.

  2017cites this paper
• Anti‐mitotic agents: Are they emerging molecules for cancer treatment?☆

  2017cites this paper
• Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer

  2017cites this paper
• KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL

  2016cites this paper
• A Novel Time-Dependent CENP-E Inhibitor with Potent Antitumor Activity

  2015cites this paper
• Clinical Trials of Mitotic Kinesin Inhibitors

  2015cites this paper
• KSP inhibitors as antimitotic agents.

  2014cites this paper
• Kinesin Spindle Protein Inhibition in Translational Research

  2014cites this paper
• Simultaneous silencing of VEGF and KSP by siRNA cocktail inhibits proliferation and induces apoptosis of hepatocellular carcinoma Hep3B cells

  2014cites this paper
• MPHOSPH1: a potential therapeutic target for hepatocellular carcinoma.

  2014cites this paper
• Target driven preclinical screening for new antimitotic chemotherapy agents.

  2014cites this paper
• Oncogenic role of kinesin proteins and targeting kinesin therapy

  2013cites this paper
• Functional Genetic Screens Identify Genes Essential for Tumor Cell Survival in Head and Neck and Lung Cancer

  2013cites this paper
• Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies

  2013influential citation
• Survival in Head and Neck and Lung Cancer Functional Genetic Screens Identify Genes Essential for Tumor Cell

  2013cites this paper
• Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer

  2013cites this paper
• Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism.

  2013cites this paper
• Resistance by allostery: a novel perspective for eg5-targeted drug design.

  2013cites this paper
• A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

  2013cites this paper
• Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.

  2013cites this paper
• Inhibitors Targeting Mitosis

  2013cites this paper
• Initial testing of the CENP‐E inhibitor GSK923295A by the pediatric preclinical testing program

  2012cites this paper
• Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia

  2012cites this paper
• Kinesins and cancer

  2012cites this paper
• Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.

  2011cites this paper
• Recent advances of kinesin motor inhibitors and their clinical progress.

  2011cites this paper
• Elucidating the functionality of kinesins: an overview of small molecule inhibitors.

  2011cites this paper
• A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

  2011cites this paper
• UA62784 Is a cytotoxic inhibitor of microtubules, not CENP-E.

  2011cites this paper
• Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors

  2011cites this paper
• Functional Characterisation and Drug Target Validation of a Mitotic Kinesin-13 in Trypanosoma brucei

  2010cites this paper
• Activity of the Kinesin Spindle Protein Inhibitor Ispinesib (SB-715992) in Models of Breast Cancer

  2010cites this paper
• Inhibitors of Kinesin Spindle Protein for the Treatment of Cancer

  2010cites this paper
• A pediatric phase I trial and pharmacokinetic study of ispinesib: A Children's Oncology Group phase I consortium study

  2010cites this paper
• Microtubule-binding agents: a dynamic field of cancer therapeutics

  2010cites this paper
• How do anti-mitotic drugs kill cancer cells?

  2009cites this paper
• Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.

  2009cites this paper
• Mitotic drivers—inhibitors of the Aurora B Kinase

  2009cites this paper
• Tumor Shrinkage and Objective Response Rates: Gold Standard for Oncology Efficacy Screening Trials, or an Outdated End Point?

  2009cites this paper
• Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program

  2009cites this paper
• Targeting the Kinesin Spindle Protein: Basic Principles and Clinical Implications

  2008cites this paper
• VU Research Portal Towards personalized and targeted treatment of head and neck cancer

  year unknowncites this paper